Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maxigen BiotechTPE:1783 +0.99%87 EBIT per Share is NT$3.38 as of Dec. 2025. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.30 (Significantly Undervalued). Among 687 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 69% on this metric.
Maxigen Biotech's EBIT per Share for the
three
months ended in Dec. 2025 was NT$1.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$3.38.
During the past 12 months, the average EBIT per Share Growth Rate of Maxigen Biotech was 29.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 23.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 28.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Maxigen Biotech's EBIT per Share or its related term are showing as below:
TPE:1783'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.3 Med: 25.7 Max: 54.5
Current: 23.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Maxigen Biotech was 54.50% per year. The lowest was -60.30% per year. And the median was 25.70% per year.
TPE:1783's 3-Year EBIT Growth Rate is ranked better than 69% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.1
vs TPE:1783: 23.50
Maxigen Biotech's EBIT for the
three
months ended in Dec. 2025 was NT$140.7 Mil.
Maxigen Biotech (TPE:1783) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Maxigen Biotech EBIT per Share Related Terms
Maxigen Biotech EBIT per Share Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a EBIT per Share of NT$3.38 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Maxigen Biotech and its competitors. According to the industry distribution chart, Maxigen Biotech ranks #213 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 31%.
Is Maxigen Biotech's EBIT per Share too high?
Maxigen Biotech's current EBIT per Share is NT$3.38. Based on the distribution chart, Maxigen Biotech ranks #213 out of 687 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #213 out of 687 companies for EBIT per Share. This puts Maxigen Biotech in the upper half of its industry. The industry median EBIT per Share is 9.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current EBIT per Share is NT$3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.30, compared to a current price of NT$40.80 — trading 33.4% below its estimated fair value. The current EBIT per Share is NT$3.38. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current EBIT per Share is NT$3.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$40.80 is trading 33.4% below its estimated GF Value™ of NT$61.30.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
EBIT per Share: NT$3.38
GF Value™: NT$61.30 vs. price of NT$40.80 (33.4% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
